Exacerbations of multiple sclerosis in patients treated with gamma interferon
Abstract
In an open, randomised study, 18 patients with clinically definite, relapsing-remitting multiple sclerosis (MS) received 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN-gamma), given by intravenous infusion twice a week for four weeks. 7 patients had exacerbations during treatment. This exacerbation rate, compared retrospectively with the pretreatment rate and prospectively with the post-treatment rate, was significantly greater than expected. Exacerbations were not precipitated by fever or other dose-dependent side-effects. A concomitant increase in circulating monocytes bearing class II (HLA-DR) surface antigen suggested that the attacks induced during treatment were immunologically mediated. IFN-gamma is unsuitable for treatment of MS.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Therapies that have been shown to work in mice have failed in human trials, and therapies that do not work in mice have shown success in humans.
“Therapies that have been shown to work in mice have failed in human trials, and therapies that do not work in mice have shown success in humans”
From Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD) (2010) · cites this paper as Panitch et al., 1987
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011 · see citing works
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962 · see citing works
Pober, J. S., Gimbrone, M. A., Cotran, R. S., Reiss, C. S., Burakoff, S. J., Fiers, W. C., & Ault, K. A. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.157.4.1339 · Cited by 628 · see citing works
Recombinant interferon-gamma increases HLA-DR synthesis and expression.
Basham, T. Y., & Merigan, T. C. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.4.1492 · Cited by 581 · see citing works
Fierz, W., Endler, B., Reske, K., et al. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3785 · Cited by 445 · see citing works
A neurologic rating scale (NRS) for use in multiple sclerosis
Sipe, J. C., Knobler, R. L., Braheny, S. L., Rice, G. P., PANITCH, H. S., & Oldstone, M. B. A. (1984) · Neurology · doi:10.1212/wnl.34.10.1368 · Cited by 254 · see citing works
Self-citationLing, P. D., Warren, M. K., & Vogel, S. N. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.3.1857 · Cited by 211 · see citing works
Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis
Jacobs, L. R., O’Malley, J. A., Freeman, A. I., et al. (1981) · Science · doi:10.1126/science.6171035 · Cited by 209 · see citing works
Multiple sclerosis (second of two parts).
Mcfarlin, D., & McFarland, H. (1982) · New England Journal of Medicine · doi:10.1056/nejm198211113072005 · Cited by 198 · see citing works
Kelley, V. E., Fiers, W., & Strom, T. B. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.1.240 · Cited by 181 · see citing works
Multiple Sclerosis as a Disease of Immune Regulation
Waksman, B. H., & Reynolds, W. E. (1984) · Experimental Biology and Medicine · doi:10.3181/00379727-175-41798 · Cited by 168 · see citing works
Sriram, S., & Steinman, L. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.4.1362 · Cited by 160 · see citing works
Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens.
Inaba, K., Kitaura, M., Kato, T., et al. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.163.4.1030 · Cited by 140 · see citing works
Systemic alpha‐interferon therapy of multiple sclerosis
Knobler, R. L., PANITCH, H. S., Braheny, S. L., et al. (1984) · Neurology · doi:10.1212/wnl.34.10.1273 · Cited by 129 · see citing works
Self-citationMcCarron, R. M., Spatz, M., Kempski, O. S., et al. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.11.3428 · Cited by 118 · see citing works
Jacobs, L. R., Herndon, R. M., Freeman, A. I., Cuetter, A. C., Smith, W., Salazar, A., Reese, P. A., Josefowicz, R., Husain, F., Ekes, R., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92730-3 · Cited by 112 · see citing works
Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration
Smith, R. A., Norris, F. H., Palmer, D., Bernhardt, L., & Wills, R. J. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.16 · Cited by 103 · see citing works
Interferon responses of leukocytes in multiple sclerosis
Neighbour, P. A., Miller, A. E., & Bloom, B. R. (1981) · Neurology · doi:10.1212/wnl.31.5.561 · Cited by 98 · see citing works
Evidence for antigen presentation in situ by endothelial cells and astrocytes
Traugott, U., & Raine, C. S. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90147-9 · Cited by 51 · see citing works
Enhancing effect of IFN-gamma on helper T cell activity and IL 2 production.
Frasca, D., Adorini, L., Landolfo, S., et al. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3907 · Cited by 48 · see citing works
Vervliet, G., Claeys, H., Haver, H. V., et al. (1983) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(83)90133-8 · Cited by 43 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120 · see citing works
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · see citing works
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523 · see citing works
Midlife sleep characteristics associated with late life cognitive function
Virta, J. J., Heikkilä, K., Perola, M., Koskenvuo, M., Räihä, I., Rinne, J. O., & Kaprio, J. (2013) · Sleep · doi:10.5665/sleep.3052 · Cited by 200 · see citing works
Devos, H., Rodd, C., Gagné, N., Laframboise, R., & Van Vliet, G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5831 · Cited by 204 · see citing works
Role of sleep-wake cycle on blood pressure circadian rhythms and hypertension
Smolensky, M. H., Hermida, R. C., Castriotta, R. J., & Portaluppi, F. (2007) · Sleep Medicine · doi:10.1016/j.sleep.2006.11.011 · Cited by 192 · see citing works
Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD)
Ramkumar, H. L., Zhang, J., & Chan, C.-C. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.02.002 · Cited by 163 · see citing works
Suryani, S., & Sutton, I. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.023 · Cited by 92 · see citing works
Liver X receptor-dependent inhibition of microglial nitric oxide synthase 2
Secor McVoy, J. R., Oughli, H. A., & Oh, U. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0247-2 · Cited by 34 · see citing works
Andsberg, U. (2000) · Acta Oto-Laryngologica · doi:10.1080/000164800454323 · Cited by 34 · see citing works
Xie, D., Li, W., Wang, Y., Gu, H., Teo, K., Liu, L., & Yusuf, S. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-531 · Cited by 32 · see citing works
Treatment of primary snoring using radiofrequency-assisted uvulopalatoplasty
Lim, D. J., Kang, S. H., Kim, B. H., & Kim, H. G. (2007) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-007-0252-x · Cited by 23 · see citing works
- Authors
- Panitch, H., Haley, A., Hirsch, R., & Johnson, K.
- Affiliations
- United States Department of Veterans Affairs (US)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1987-04
- Volume
- 329
- Issue
- 8538
- Pages
- 893-895
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2057939648
- Cited by
- 1,071
- References
- 21
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 15 · 2023: 13 · 2022: 13 · 2021: 14 · 2020: 15 · 2019: 23 · 2018: 20 · 2017: 35 · 2016: 32 · 2015: 44 · 2014: 37 · 2013: 30 · 2012: 30
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (NS 20022.)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- multiple sclerosis, relapsing-remitting multiple sclerosis, interferon-gamma, dose-dependent side effects, HLA-DR monocytes, immunomodulation, treatment safety
- MeSH terms
- Adult, Female, Humans, Interferon-gamma, Male, Multiple Sclerosis, Pilot Projects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
